Neuroblastoma (NB) is a stroma-poor (SP) aggressive pediatric cancer belonging to Neuroblastic Tumors (NTs), also including ganglioneuroblastoma and ganglioneuroma, two stroma-rich (SR) less aggressive tumors. Our previous gene expression profiling analysis showed a different CXCL13 mRNA expression between SP and SR tumors. Therefore, we studied 13 SP and 13 SR tumors by RT-qPCR and we found that CXCR5b was more expressed in SP than in SR and CXCL13 was predominantly expressed in SR tumors. Then, we isolated neuroblastic and Schwannian stromal cells by laser capture microdissection and we found that malignant neuroblasts express CXCR5b mRNA, whereas Schwannian stromal cells express CXCL13. Immunohistochemistry confirmed that stroma expresses CXCL13 but not CXCR5. To better understand the role of CXCL13 and CXCR5 in NTs we studied 11 NB cell lines and we detected a heterogeneous expression of CXCL13 and CXCR5b. Interestingly, we found that only CXCR5b splice variant was expressed in both tumors and NB lines, whereas CXCR5a was never detected. Moreover, we found that NB cells expressing CXCR5 receptor migrate towards a source of recombinant CXCL13. Lastly, NB cells induced to glial cell differentiation expressed CXCL13 mRNA and protein. The chemokine released in the culture medium was able to stimulate chemotaxis of LA1-5S NB cells. Collectively, our data suggest that CXCL13 produced by stromal cells may contribute to the generation of an environment in which the malignant neuroblasts are retained, thus limiting the possible development of metastases in patients with stroma-rich tumor.
Introduction
Neuroblastic Tumors (NTs) are a group of pediatric cancers that onset as localized or disseminated disease (1) . Patients with localized tumor have good prognosis with a 3-years overall survival (OS) of 90-95%, whereas patients older than one year with a disseminated disease have a worse prognosis with a 3-years OS ranging between 30% and 35%. This dramatic behavior of the metastatic disease is mainly due to the capacity of neuroblastoma (NB) cells to metastasize at bone, bone marrow, liver and lymph nodes. Particularly, in patients with disseminated disease, the normal bone marrow cell population is almost completely substituted by malignant neuroblasts that find a favorable environment for their proliferation.
NTs show a quite heterogeneous histology with different tumor histotypes including: neuroblastoma predominantly composed of small round undifferentiated or poorly differentiated neuroblastic cells, with few or absent Schwannian stromal cells, ganglioneuroblastoma intermixed (GNB) and ganglioneuroma (GN) mostly composed of Schwannian stromal cells in which some nests or very few neuroblastic cells are present (2) . The absence of stromal cells makes the tumor more aggressive and patients have a worse outcome. On the contrary, the abundance of Schwannian stromal cells, as observed in GNB and GN, is associated with a less aggressive tumor and a localized disease with a more favorable prognosis (1, 3) .
Several evidences support a non-malignant origin of Schwannian stromal cells (4, 5) , which are supposed to control tumor growth by secreting soluble factors that influence cell proliferation, differentiation and angiogenesis. Indeed, various molecules have been found expressed by Schwannian stromal cells (6, 7) , although their role in controlling neuroblastic cells growth and 
Isolation of neuroblastic and Schwannian stromal cells by laser capture microdissection and
total RNA extraction. About 800 cells were laser microdissected from 3 SP and 3 SR frozen tumors in order to obtain pure cell populations of neuroblastic cells and Schwannian stromal cells, as previously described (8) . Total RNA from laser capture microdissection-derived material was extracted by PicoPure TM RNA isolation kit (Arcturus Engineering, CA, USA), including a DNase treatment, RNA quality control and quantification wereas performed by RNA 6000 Pico LabChip kit and the 2100 BioAnalyzer instrument (Agilent Technologies). 
Reverse transcription quantitative real-time PCR (RT-qPCR

Glial differentiation assays. N-type (SH-SY5Y), I-type (SK-N-BE(2)c) and S-type (LA1-5S) NB
cell lines were grown by adding 10 mM 5'-Bromo-2'-deoxyuridine (BrdU) (Sigma Aldrich, Inc., San Louis, MO, USA) to cell culture medium to induce glial differentiation (19) . Treatment was CXCL13 was pre-coated onto a microplate. Human recombinant CXCL13 (hrCXCL13) standards, saliva, untreated and BrdU differentiated NB cells conditioned media were pipetted into the wells and CXCL13 was bound by the immobilized antibody. After washing, an enzyme-linked monoclonal antibody specific for CXCL13 was added. After incubation and extensive washing, a substrate solution was added and the amount of CXCL13 was quantified by a colorimetric measurement on a standard curve of serial dilution of hrCXCL13.
NB cell migration assay. Cell migration assays were performed on SH-SY5Y, ACN and LA1-5S cells in microchambers (NeuroProbes Gaithersburg, MD, USA) as previously described (20) . Cells were extensively washed with PBS, re-suspended in serum-free medium, and placed in the upper compartment. The two compartments of the chamber were separated by 5 μm pore size polycarbonate filters coated with 0.01% gelatine. The hrCXCL13 (100 or 200 ng/ml) and concentrated serum-free conditioned medium from BrdU-differentiated NB cells were used as chemoattractants in the lower chamber. To obtain specific neutralization of hrCXCL13 bioactivity a blocking anti-human CXCL13/BLC/BCA-1 goat antibody (R&D Systems, Inc) was added to hrCXCL13 and to BrdU differentiated NB cells conditioned medium in the lower chamber at 3.5 μg/ml and 0.5 μg/ml, respectively. In order to specifically neutralize CXCR5 receptor on NB cell surface, cells were previously incubated 30 minutes with 15 μg/ml blocking monoclonal anti-human CXCR5/BLR1 mouse antibody (R&D Systems, Inc). After 6 hours of incubation at 37°C in 5% CO 2 , the filters were recovered, the cells on the upper surface were mechanically removed, and the cells on the lower surface were fixed and stained. Figure 3C , Schwannian stromal cells strongly express CXCL13, whereas CXCR5 is not expressed in the same tissue ( Figure 3D ). Since CXCR5b mRNA was found variable expressed we employed immunofluorescence technique to have a better sensibility to detect CXCR5 expression. CXCR5 protein was observed in neuroblastic cells ( Figure 3E and 3F ), but not in SR tumors (data not shown).
Next, we analyzed SH-SY5Y and LA1-5S NB cell lines by either immunofluorescence ( Figure 3G and 3H) or immunohistochemistry ( Figure 3I and 3L) and we observed a mild surface expression of CXCR5 receptor in about 20% of SH-SY5Y and 30% of LA1-5S NB cells, respectively ( Figure 3G and 3H). Immunofluorescence analysis also showed some cytoplasmic staining, possibly related to a CXCR5 internalization. Immunofluorescence analysis was also performed in the other NB cell lines with similar results and we confirmed CXCR5 expression in SK-N-BE(2), SK-N-BE(2)c and
SK-N-SH cells by FACS analysis (data not shown). Although IMR-5, SK-N-SH and GI-LI-N,
expressed CXCL13 mRNA, only IMR-5 showed CXCL13 cytoplasmatic expression but the secreted protein was not detected (data not shown). Figure 4A ). In addition, a variable de novo CXCL13 mRNA induction was detected in NB cell lines reaching a maximum at 3 weeks in BrdU-differentiated SK-N-BE(2)c cells ( Figure   4B ). The secretion of CXCL13 protein in the culture medium was remarkable in differentiated SK-N-BE(2)c and LA1-5S ( Figure 4C ).
Induction of NB cells to glial differentiation
Triggering of NB cells migration by CXCL13. We tested whether the expression of CXCR5
could be sufficient to trigger NB cell migration in response to CXCL13 stimulation by chemotaxis assays. Figure 5A shows that the CXCR5-positive SH-SY5Y and LA1-5S cells significantly migrated in presence of hrCXCL13 chemokine, while the CXR5-negative ACN cells failed to migrate (p = not significant, data not shown). LA1-5S cell migration was inhibited by either blocking the receptor or the chemokine activity, following addition of specific antibodies against CXCR5 or hrCXCL13 ( Figure 5B ). LA1-5S cell migration was also observed when the conditioned medium of NB cells differentiated to the glial cell lineage were used as chemoattractants, thus further substantiating the possibility that cell-released CXCL13 induces NB cell migration ( Figure   5C ). This result shows that NB cells induced to glial cell lineage and acquiring a Schwannian-like Figure 5C ).
Discussion
Chemokines play several roles in both physiological and pathological conditions. Hereby, we show that CXCL13 and its receptor CXCR5 are involved in the relation between neuroblastic and Schwannian stromal cells of NTs, a heterogeneous group of pediatric cancers. Several chemokines have been found expressed in NB; in particular, the role of the CXCR4-CXCL12 axis in NB cells proliferation, survival and in bone marrow dissemination is still controversial (13, 14, 22) . Airoldi et al. (15) showed that NB cells express CXCR5 and they hypothesized that malignant cells are able to migrate even in the bone marrow in response to CXCL13 stimulation.
We confirm that NB cells express CXCR5 receptor and we add a detailed analysis of CXCL13 and 
